Thermo Fisher Scientific Inc. (NYSE:TMO) – Analysts at Leerink Swann issued their Q1 2017 EPS estimates for Thermo Fisher Scientific in a research note issued to investors on Wednesday. Leerink Swann analyst P. Souda anticipates that the firm will post earnings of $2.19 per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $175.00 target price on the stock. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q2 2017 earnings at $2.33 EPS, Q3 2017 earnings at $2.32 EPS, FY2018 earnings at $10.37 EPS and FY2019 earnings at $11.75 EPS.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, October 27th. The company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.97 by $0.06. Thermo Fisher Scientific had a return on equity of 14.95% and a net margin of 11.10%. The company earned $4.49 billion during the quarter, compared to analysts’ expectations of $4.39 billion. During the same period in the prior year, the business earned $1.80 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 8.9% compared to the same quarter last year.

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

TMO has been the topic of several other research reports. Jefferies Group restated a “hold” rating on shares of Thermo Fisher Scientific in a research note on Thursday, August 4th. BTIG Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Friday, July 22nd. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Mizuho set a $175.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, July 28th. Finally, Citigroup Inc. boosted their target price on Thermo Fisher Scientific from $160.00 to $182.00 and gave the company a “buy” rating in a research note on Friday, July 29th. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $164.37.

Shares of Thermo Fisher Scientific (NYSE:TMO) opened at 151.25 on Friday. The stock has a 50 day moving average price of $152.92 and a 200 day moving average price of $151.85. The company has a market capitalization of $59.75 billion, a PE ratio of 30.23 and a beta of 1.24. Thermo Fisher Scientific has a 52-week low of $119.75 and a 52-week high of $160.68.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 16th. Shareholders of record on Thursday, December 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Tuesday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is 12.00%.

In other news, SVP Daniel P. Shine sold 1,699 shares of the company’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $152.28, for a total transaction of $258,723.72. Following the completion of the sale, the senior vice president now directly owns 17,437 shares in the company, valued at approximately $2,655,306.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 30,000 shares of the company’s stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $151.17, for a total value of $4,535,100.00. Following the sale, the chief executive officer now owns 308,647 shares of the company’s stock, valued at $46,658,166.99. The disclosure for this sale can be found here. 0.52% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in TMO. American Research & Management Co. increased its stake in Thermo Fisher Scientific by 540.0% in the third quarter. American Research & Management Co. now owns 640 shares of the company’s stock worth $102,000 after buying an additional 540 shares during the last quarter. Mycio Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 1.6% in the second quarter. Mycio Wealth Partners LLC now owns 711 shares of the company’s stock worth $105,000 after buying an additional 11 shares during the last quarter. Signaturefd LLC increased its stake in Thermo Fisher Scientific by 10.6% in the second quarter. Signaturefd LLC now owns 842 shares of the company’s stock worth $124,000 after buying an additional 81 shares during the last quarter. Penserra Capital Management LLC increased its stake in Thermo Fisher Scientific by 100.0% in the third quarter. Penserra Capital Management LLC now owns 864 shares of the company’s stock worth $137,000 after buying an additional 432 shares during the last quarter. Finally, Global X Management Co. LLC increased its stake in Thermo Fisher Scientific by 73.5% in the third quarter. Global X Management Co. LLC now owns 1,105 shares of the company’s stock worth $176,000 after buying an additional 468 shares during the last quarter. Hedge funds and other institutional investors own 87.80% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Receive News & Stock Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related stocks with our FREE daily email newsletter.